Mineralys Therapeutics (NASDAQ:MLYS) Receives Outperform Rating from Lifesci Capital

Mineralys Therapeutics (NASDAQ:MLYS)‘s stock had its “outperform” rating reissued by research analysts at Lifesci Capital in a research note issued on Tuesday, Zacks.com reports. Lifesci Capital also issued estimates for Mineralys Therapeutics’ FY2024 earnings at ($2.04) EPS.

Mineralys Therapeutics Trading Down 0.5 %

NASDAQ:MLYS opened at $12.78 on Tuesday. The stock has a market cap of $634.27 million and a P/E ratio of -6.39. The stock’s 50-day moving average is $13.17 and its 200-day moving average is $10.10. Mineralys Therapeutics has a 1-year low of $5.85 and a 1-year high of $17.70.

Mineralys Therapeutics (NASDAQ:MLYS) last released its quarterly earnings results on Thursday, March 21st. The company reported ($0.61) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.24. As a group, equities analysts forecast that Mineralys Therapeutics will post -2.64 EPS for the current year.

Insider Activity at Mineralys Therapeutics

In related news, major shareholder Samsara Biocapital Gp, Llc bought 555,555 shares of Mineralys Therapeutics stock in a transaction that occurred on Monday, February 12th. The shares were acquired at an average cost of $13.50 per share, for a total transaction of $7,499,992.50. Following the completion of the acquisition, the insider now directly owns 5,074,916 shares of the company’s stock, valued at approximately $68,511,366. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Hedge Funds Weigh In On Mineralys Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Catalys Pacific LLC bought a new position in shares of Mineralys Therapeutics during the 4th quarter worth approximately $79,073,000. Samsara BioCapital LLC bought a new position in shares of Mineralys Therapeutics during the 1st quarter worth approximately $70,773,000. Braidwell LP boosted its holdings in shares of Mineralys Therapeutics by 267.8% during the 3rd quarter. Braidwell LP now owns 2,023,900 shares of the company’s stock worth $19,247,000 after buying an additional 1,473,600 shares in the last quarter. FMR LLC boosted its holdings in shares of Mineralys Therapeutics by 62.6% during the 3rd quarter. FMR LLC now owns 1,188,653 shares of the company’s stock worth $11,304,000 after buying an additional 457,815 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Mineralys Therapeutics by 4.3% during the 4th quarter. Vanguard Group Inc. now owns 977,980 shares of the company’s stock worth $8,411,000 after buying an additional 40,342 shares in the last quarter. 84.46% of the stock is currently owned by institutional investors.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension.